Show simple item record

dc.contributor.authorStephens, Richard J
dc.contributor.authorDearnaley, David P
dc.contributor.authorCowan, Richard A
dc.contributor.authorSydes, Matthew R
dc.contributor.authorNaylor, Sharon
dc.contributor.authorFallowfield, Lesley J
dc.date.accessioned2009-06-30T11:58:26Z
dc.date.available2009-06-30T11:58:26Z
dc.date.issued2007-02
dc.identifier.citationThe quality of life of men with locally advanced prostate cancer during neoadjuvant hormone therapy: data from the Medical Research Council RT01 trial (ISRCTN 47772397). 2007, 99 (2):301-10 BJU Int.en
dc.identifier.issn1464-4096
dc.identifier.pmid17155990
dc.identifier.doi10.1111/j.1464-410X.2006.06560.x
dc.identifier.urihttp://hdl.handle.net/10541/71926
dc.description.abstractOBJECTIVE: To explore patients' quality of life (QoL) during neoadjuvant hormone therapy (HT) using data from the Medical Research Council RT01 trial of standard- (64 Gy/32-fraction) and high- (74 Gy/37-fraction) dose radiotherapy (RT, both given conformally). PATIENTS AND METHODS: Of the 843 patients randomized to the RT01 trial, 316 completed the Functional Assessment Of Cancer Therapy core questionnaire with its additional prostate subscale, and the Short Form-36 Health Survey questionnaire with the University of California-Los Angeles Prostate Cancer Index before HT and again before starting RT. Three predefined QoL hypotheses were generated to focus the analyses. RESULTS: For the three primary QoL analyses there was evidence that sexual functioning deteriorated, urinary function did not change, and there was a slight decline in physical well-being after > or = 3 months of HT. Sensitivity analyses confirmed these findings. Exploratory analyses also suggested that role functioning deteriorated, sleep was more disturbed, and there was an increase in fatigue. However, overall QoL was not reported to be affected and patients indicated an improvement in attitude and satisfaction with treatment. CONCLUSIONS: In this group of men, many of whom reported reduced sexual functioning before treatment, the additional decline during HT seemed to be generally accepted as the price to pay for an appropriate cancer treatment. Nevertheless, these changes need to be discussed with patients before HT is commenced.
dc.language.isoenen
dc.subjectProstate Canceren
dc.subjectHormone Therapyen
dc.subject.meshAged
dc.subject.meshAndrogen Antagonists
dc.subject.meshAntineoplastic Agents, Hormonal
dc.subject.meshAttitude to Health
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshNeoadjuvant Therapy
dc.subject.meshPatient Satisfaction
dc.subject.meshProstatic Neoplasms
dc.subject.meshQuality of Life
dc.subject.meshQuestionnaires
dc.subject.meshSexual Dysfunction, Physiological
dc.subject.meshTreatment Outcome
dc.titleThe quality of life of men with locally advanced prostate cancer during neoadjuvant hormone therapy: data from the Medical Research Council RT01 trial (ISRCTN 47772397).en
dc.typeArticleen
dc.contributor.departmentCancer Group, MRC Clinical Trials Unit, London, UK. rs@ctu.mrc.ac.uken
dc.identifier.journalBJU Internationalen
html.description.abstractOBJECTIVE: To explore patients' quality of life (QoL) during neoadjuvant hormone therapy (HT) using data from the Medical Research Council RT01 trial of standard- (64 Gy/32-fraction) and high- (74 Gy/37-fraction) dose radiotherapy (RT, both given conformally). PATIENTS AND METHODS: Of the 843 patients randomized to the RT01 trial, 316 completed the Functional Assessment Of Cancer Therapy core questionnaire with its additional prostate subscale, and the Short Form-36 Health Survey questionnaire with the University of California-Los Angeles Prostate Cancer Index before HT and again before starting RT. Three predefined QoL hypotheses were generated to focus the analyses. RESULTS: For the three primary QoL analyses there was evidence that sexual functioning deteriorated, urinary function did not change, and there was a slight decline in physical well-being after > or = 3 months of HT. Sensitivity analyses confirmed these findings. Exploratory analyses also suggested that role functioning deteriorated, sleep was more disturbed, and there was an increase in fatigue. However, overall QoL was not reported to be affected and patients indicated an improvement in attitude and satisfaction with treatment. CONCLUSIONS: In this group of men, many of whom reported reduced sexual functioning before treatment, the additional decline during HT seemed to be generally accepted as the price to pay for an appropriate cancer treatment. Nevertheless, these changes need to be discussed with patients before HT is commenced.


This item appears in the following Collection(s)

Show simple item record